{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T05:04:43Z","timestamp":1664255083213},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-022-04123-y","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T05:02:51Z","timestamp":1659762171000},"page":"2585-2586","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comment on \u201cTadalafil monotherapy in management of chronic prostatitis\/chronic pelvic pain syndrome: a randomized double\u2011blind placebo controlled clinical trial\u201d"],"prefix":"10.1007","volume":"40","author":[{"given":"Yongfeng","family":"Lao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhilong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,6]]},"reference":[{"key":"4123_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-022-04074-4","author":"AM Tawfik","year":"2022","unstructured":"Tawfik AM et al (2022) Tadalafil monotherapy in management of chronic prostatitis\/chronic pelvic pain syndrome: a randomized double-blind placebo controlled clinical trial. World J Urol. https:\/\/doi.org\/10.1007\/s00345-022-04074-4","journal-title":"World J Urol"},{"issue":"7","key":"4123_CR2","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1007\/s00330-020-07663-2","volume":"31","author":"P Xiang","year":"2021","unstructured":"Xiang P et al (2021) Efficacy and safety of prostatic artery embolization for benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. Eur Radiol 31(7):4929\u20134946","journal-title":"Eur Radiol"},{"issue":"4","key":"4123_CR3","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/JU.0000000000002183","volume":"206","author":"LB Lerner","year":"2021","unstructured":"Lerner LB et al (2021) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I\u2014initial work-up and medical management. J Urol 206(4):806\u2013817","journal-title":"J Urol"},{"issue":"10","key":"4123_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/pros.23514","volume":"78","author":"K Okamoto","year":"2018","unstructured":"Okamoto K et al (2018) Effect of tadalafil on chronic pelvic pain and prostatic inflammation in a rat model of experimental autoimmune prostatitis. Prostate 78(10):707\u2013713","journal-title":"Prostate"},{"issue":"5","key":"4123_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/pros.23750","volume":"79","author":"H Yamaguchi","year":"2019","unstructured":"Yamaguchi H et al (2019) Voiding behavior and chronic pelvic pain in two types of rat nonbacterial prostatitis models: attenuation of chronic pelvic pain by repeated administration of tadalafil. Prostate 79(5):446\u2013453","journal-title":"Prostate"},{"issue":"12","key":"4123_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1756287218808677","volume":"10","author":"A Benelli","year":"2018","unstructured":"Benelli A et al (2018) Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis\/chronic pelvic pain syndrome. Ther Adv Urol 10(12):377\u2013381","journal-title":"Ther Adv Urol"},{"issue":"1","key":"4123_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/nau.24551","volume":"40","author":"A Gaspar","year":"2021","unstructured":"Gaspar A et al (2021) Nonablative transurethral Erbium:YAG laser treatment for chronic prostatitis\/chronic pelvic pain syndrome: a prospective comparative study. Neurourol Urodyn 40(1):278\u2013285","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"4123_CR8","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/nau.24454","volume":"39","author":"Y Matsukawa","year":"2020","unstructured":"Matsukawa Y et al (2020) Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis\/chronic pelvic pain syndrome: a randomized, prospective study. Neurourol Urodyn 39(7):1994\u20132002","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"4123_CR9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jiac.2022.01.005","volume":"28","author":"K Ichihara","year":"2022","unstructured":"Ichihara K et al (2022) Distribution of the positive UPOINT domain in patients with chronic prostatitis or chronic pelvic pain syndrome: a multicenter observational study. J Infect Chemother 28(5):631\u2013634","journal-title":"J Infect Chemother"},{"issue":"3","key":"4123_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4103\/aja.aja_71_20","volume":"23","author":"XC Li","year":"2021","unstructured":"Li XC et al (2021) Is mild erectile dysfunction associated with severe psychological symptoms in Chinese patients with moderate-to-severe chronic prostatitis\/chronic pelvic pain syndrome? Asian J Androl 23(3):319\u2013324","journal-title":"Asian J Androl"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04123-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-022-04123-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04123-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T16:08:59Z","timestamp":1664208539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-022-04123-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,6]]},"references-count":10,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["4123"],"URL":"https:\/\/doi.org\/10.1007\/s00345-022-04123-y","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,6]]},"assertion":[{"value":"25 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}